AAP
TARS icon

Arax Advisory Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Arax Advisory Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46K Buy
+55
New +$3.51K ﹤0.01% 4685
2026
Q1 		– Sell
-132
Closed -$10.8K – 4304
2025
Q4 		$10.8K Buy
132
+86
+187% +$6.42K ﹤0.01% 2427
2025
Q3 		$2.73K Buy
+46
New +$2.27K ﹤0.01% 3033

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's TARS Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 55 shares worth $3.46K. The stake represents ﹤0.01% of the portfolio and ranks #4685 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in TARS as recently as Q4 2025.

Arax Advisory Partners first reported a position in TARS in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.8K in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Arax Advisory Partners held 55 shares of Tarsus Pharmaceuticals worth $3.46K as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4685 holding.
  • Arax Advisory Partners first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Tarsus Pharmaceuticals position peaked at $10.8K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.